Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
57.73
-1.97 (-3.30%)
At close: Mar 6, 2026, 4:00 PM EST
58.28
+0.55 (0.95%)
After-hours: Mar 6, 2026, 6:49 PM EST
Structure Therapeutics Employees
Structure Therapeutics had 220 employees as of December 31, 2025. The number of employees increased by 57 or 34.97% compared to the previous year.
Employees
220
Change (1Y)
57
Growth (1Y)
34.97%
Revenue / Employee
n/a
Profits / Employee
-$647,716
Market Cap
4.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 220 | 57 | 34.97% |
| Dec 31, 2024 | 163 | 70 | 75.27% |
| Dec 31, 2023 | 93 | 25 | 36.76% |
| Dec 31, 2022 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| ACADIA Pharmaceuticals | 798 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 685 |
| Crinetics Pharmaceuticals | 594 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 374 |
| Centessa Pharmaceuticals | 114 |
GPCR News
- 8 days ago - Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 16 days ago - Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? - Seeking Alpha
- 4 weeks ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters
- 6 weeks ago - Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
- 3 months ago - Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs - GlobeNewsWire
- 3 months ago - Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade) - Seeking Alpha
- 3 months ago - Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript - Seeking Alpha